Fluditec

Quick links to important sections

Fluditec

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Fluditec

Property Description
Active ingredient Carbocisteine (S-Carboxymethyl-L-cysteine)
Form Oral Solution (Syrup), Capsules
Pharmacological class Mucolytic Agent (R05CB03)
Common use Clearing thick, viscous bronchial secretions
Origin Synthetic derivative of L-cysteine

Definition, Origin, and Pharmacological Classification

Fluditec is a pharmaceutical preparation whose single active component is Carbocisteine, a synthetic compound derived from the amino acid L-cysteine. This medicine is defined as a mucolytic agent and holds the international classification code R05CB03. As a modified molecule, Carbocisteine is distinguished within its class by its targeted action and its ability to modify the physical properties of mucus.

The drug's primary distinction is its specific mucoregulatory function. Carbocisteine is used in the management of respiratory disorders associated with increased mucus viscosity, acting as a secretolytic agent. This medicine helps manage the quality and thickness of respiratory secretions, which is the defining characteristic of its class.


Composition, Forms, and General Therapeutic Purpose

The general therapeutic purpose of Fluditec is to fluidify excessively viscous bronchial secretions, making them easier to clear from the respiratory tract. The medicine is formulated for the oral route of administration and is a single-ingredient product, commonly available as an oral solution (syrup), a form often preferred for pediatric and adolescent patient groups, and as capsules.

The composition is designed to deliver Carbocisteine systemically, where the active substance modifies the mucus structure at a molecular level to reduce its stickiness. Mucolytics like Carbocisteine are used to improve symptoms in patients with conditions involving difficulty in expectorating thick phlegm. The convenience of the liquid formulation, available in different concentrations, serves the general benefit of facilitating the body’s natural process of clearing thick, sticky phlegm from the airways, a typical scenario during acute respiratory congestion.

What side effects are possible with Fluditec?

Possible Side Effects and Safety Information

The safety profile for Carbocisteine (Fluditec) is derived from official regulatory documents, which categorize potential adverse reactions primarily by frequency and the body system affected.


Officially Documented Adverse Reactions

The most frequently observed adverse events are generally related to the Gastrointestinal System and are classified as Common (affecting up to 1 in 10 people). These can include nausea, vomiting, diarrhea, and general gastrointestinal discomfort. Regulatory safety notes indicate these effects are often more prominent at the beginning of treatment.

Adverse reactions affecting the Skin and Subcutaneous Tissue and the Immune System are also documented, with some instances reported through post-marketing surveillance, such as allergic skin rashes and anaphylactic reactions, whose frequency is Not Known.


Serious Adverse Reactions and Restrictions

Official labeling records rare but severe adverse events, classified as Very Rare (affecting fewer than 1 in 10,000 people). These include serious cutaneous reactions such as Stevens-Johnson Syndrome (SJS) and Erythema Multiforme. Gastrointestinal bleeding is also documented as a serious adverse reaction.

The regulatory label establishes specific constraints for use. Carbocisteine is contraindicated and must not be used in individuals with an active peptic ulcer or a history of gastrointestinal ulceration, due to the documented risk of bleeding. Furthermore, it is strictly contraindicated in children under two years of age due to the physiological risk of bronchial obstruction.

Overdose and Emergency Response

The official regulatory documents define the overdose profile of Carbocisteine, the active component in Fluditec, based strictly on documented clinical experience. Overdosage primarily involves the gastrointestinal system.

The most frequent clinical signs of over-ingestion are gastrointestinal disturbances. Officially documented manifestations typically include nausea, vomiting, and localized abdominal pain or gastralgia. The most serious outcome officially associated with substantial overdosage is the potential for gastrointestinal bleeding. This risk is heightened, requiring caution, particularly in patients with pre-existing gastrointestinal conditions, such as a history of gastroduodenal ulcers.

Regulators mandate that upon any suspected or confirmed overdose, the user must seek immediate medical attention and contact emergency services or a hospital immediately. The official treatment approach is defined as symptomatic and supportive treatment. This strategy is required because the regulatory information notes that no specific antidote is known for Carbocisteine overdose. Clinical management may involve procedures such as gastric lavage or continuous hospital observation, depending on the clinical assessment of the amount and timing of the ingestion.

Therapeutic Uses of Fluditec

What Fluditec Treats: Main Uses and Benefits

Fluditec is commonly used across therapeutic domains where patients experience symptoms that interfere with daily functioning due to excessively viscous mucus or phlegm. The medication is applied in addressing conditions marked by increased physiological stress, such as Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis, in situations involving persistent secretion-related symptoms.

Management of Secretion-Related Symptoms

This medication is generally relevant when symptoms related to physical discomfort are related to difficulty in clearing retained secretions. It is applied in clinical settings that involve acute or unstable symptom patterns, offering symptomatic relief that helps ease the overall symptom burden. It is commonly used for managing symptoms in conditions such as Chronic Obstructive Pulmonary Disease, Chronic Bronchitis, and Otitis Media with Effusion (Glue Ear).

Fluditec is considered relevant for easing symptom clusters that may become intense or disruptive in patients with established, long-term respiratory tract disorders. It supports the patient during difficult episodes by easing distress associated with chronic mucus retention, and may assist with maintaining functional stability by contributing to the supportive management of symptom flare-ups associated with mucus buildup. It is relevant in scenarios where additional management of discomfort is required.


Quick Fact: Relief for Viscous Phlegm Fluditec is relevant for managing symptoms that interfere with daily comfort when thick, sticky mucus creates noticeable functional strain.

Eligibility and Restrictions for Use

Official Eligibility and Restrictions for Fluditec

Regulatory documents define specific populations who are permitted, restricted, or strictly contraindicated from using Fluditec (Carbocisteine). This information is based solely on official labeling from national health authorities.

Absolute Contraindications

Fluditec is strictly contraindicated in several groups, meaning use is prohibited:

  • Patients with active peptic ulceration.
  • Individuals with known hypersensitivity to Carbocisteine or any of the product’s inactive ingredients.
  • Children under the age of two years.

Restricted and Conditional Use

Use is subject to caution or is generally not recommended for the following populations:

  • Pregnancy and Lactation: Use is not recommended during pregnancy (especially the first trimester) or while breastfeeding, due to insufficient human data in these populations.
  • Gastrointestinal History: Caution is advised for the elderly and patients who have a history of gastroduodenal ulcers.
  • Metabolic Disorders: Specific formulations may be restricted for patients with rare hereditary issues like galactose intolerance due to excipients.

Fluditec is generally approved for use in adults and children aged two years and above, provided none of the absolute contraindications are present.

What should I know about interactions with other medicines?

Fluditec Interactions with other medicines and products

The official regulatory profile for Carbocisteine (Fluditec) is defined primarily by pharmacodynamic effects that result in either an antagonistic therapeutic effect or an additive risk for an adverse event. Standard pharmacokinetic interactions, such as those involving CYP enzymes, are typically reported as not documented in regulatory prescribing information.

Documented Pharmacodynamic Interactions

Co-administration with certain medicinal products results in an official interaction-related restriction, often classified as an irrational combination because the drugs oppose the mucolytic action of Carbocisteine:

  • Antitussives (Cough Suppressants): Combination is noted as irrational due to the conflict between suppressing the cough reflex and the need to facilitate the clearance of fluidified mucus.
  • Secretions-Drying Agents: Medicines that reduce or dry out bronchial secretions are considered irrational to combine, as their action negates the fluidifying goal of Carbocisteine.

Additive Risk and Population Constraints

A separate additive pharmacodynamic risk exists with medicines known to compromise the gastric mucosa. Caution is required when Carbocisteine is co-administered with agents that increase the risk of gastrointestinal bleeding or ulceration, such as non-steroidal anti-inflammatory drugs (NSAIDs) or corticosteroids. This additive risk is a specific concern and requires particular precaution in elderly patients and in individuals with a history of gastroduodenal ulcers, according to regulatory warnings.

Mechanism of Action

How Carbocisteine Modulates Airway Secretions

Fluditec’s active ingredient, Carbocisteine, functions through both direct mucolytic action and cellular mucoregulatory signaling. Its primary mechanism involves chemically disrupting the disulfide bonds ( S-S) that cross-link the high-molecular-weight mucin glycoproteins, the structural components responsible for high mucus viscosity. This depolymerization reduces the mucus's viscoelasticity, which subsequently enhances the efficiency of the mucociliary transport system to facilitate the physiological clearance of secretions.

Simultaneously, Carbocisteine modulates intracellular processes by stimulating the enzyme Sialyl Transferase within the respiratory epithelial cells. This enzyme activation shifts the chemical composition of newly secreted mucus toward less adhesive sialomucins, affecting secretion quality. Furthermore, the molecule acts on key signaling pathways, including suppression of the pro-inflammatory NF-kappa B pathway and activation of the cytoprotective KEAP1/NRF2 system. This modulation of transcription factors mitigates molecular stress on the respiratory epithelium and influences the extent of inflammation-driven hypersecretion, affecting the stability of the airway lining.

Dosage and Administration Information

How to Use Fluditec

Fluditec, which contains Carbocisteine, is administered exclusively via the oral route, typically available as capsules or oral solutions (syrups). The administration protocol is standardized across age groups and is based on specific dose amounts and frequency patterns.


Adult Dosing and Frequency

For adults, treatment typically follows a tiered regimen. It begins with an initial daily dose of 2,250 mg, which must be taken in divided doses throughout the day. This total amount is reduced to a maintenance dose of 1,500 mg daily once a response is achieved. The dosing schedule commonly requires administration three times a day (TID). The medicine can be taken with or without food, providing flexibility in the patient's daily schedule.


Pediatric Use and Duration

Specific daily doses are established for children based on age. Children aged 2 to 5 years are generally prescribed 100 mg to 200 mg per day, while those aged 5 to 12 years are given 300 mg per day, both split into multiple doses. The use of Carbocisteine is not approved for children under two years of age.

Treatment for acute conditions should generally not exceed 8 to 10 days without medical re-evaluation. A standard procedural instruction is to avoid co-administration with antitussive (cough suppressant) agents, as this may counteract the intended therapeutic action. When administering the liquid form, a calibrated measuring device must be used to ensure accurate dosing.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Fluditec


Evidence for Use in Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis

The clinical evidence base, including Randomized Controlled Trials (RCTs), has explored Fluditec in the context of COPD and Chronic Bronchitis, which are conditions characterized by fluctuating or episodic manifestations. The evidence base includes RCTs and Systematic Reviews that was evaluated in long periods, with many trials including adults and older adults. Researchers monitored outcomes describing episodic or acute changes, primarily focusing on the annual rate of acute disease exacerbations (or flare-ups) and patient-reported outcomes describing perceived discomfort and health-related quality of life.

Some long-term studies, which sometimes lasted up to a year or more, reported data on the frequency of these flare-ups. The research monitored changes in patient-reported outcomes related to physical discomfort, and some studies described patterns in the reported quality of life. However, research explores consistent changes in objective lung function measures observed in the studies, and findings were mixed across various studies on this specific outcome.


Evidence for Use in Otitis Media with Effusion (OME) / Glue Ear

Fluditec was evaluated in trials where OME was the condition under study, which is often called "glue ear." These trials were primarily Randomized Controlled Trials and studies conducted during periods of increased symptom activity focused on children and pediatric patient groups. Research examined whether middle ear fluid resolution occurred and monitored auditory outcomes, such as changes in hearing, as well as the need for surgical interventions like grommet insertion.


What is Still Uncertain About Fluditec Research

The scientific literature identifies several areas where the evidence is limited or requires further research. Key uncertainties relate to the medicine's influence on lung function measures (such as FEV1), where findings were mixed and data show patterns related to limited measurable impact.

Furthermore, evidence quality varies across studies, and the follow-up durations were limited in research addressing acute symptom changes. Comparative evidence is lacking for many direct assessments against other types of medicine.

Key Studies & References

  1. National Institute for Health and Care Excellence (NICE): Chronic obstructive pulmonary disease in over-16s: diagnosis and management

Frequently Asked Questions (FAQ)

Common questions about Fluditec (FAQ)


Q: What specific respiratory conditions is Fluditec typically indicated for?

A: Official regulatory documents indicate that Fluditec is used as an adjunctive therapy for respiratory tract disorders characterized by the presence of excessive, viscous mucus. This can include conditions such as chronic obstructive airways disease.


Q: Are there known drug interactions between Fluditec and common over-the-counter cold and flu medications?

A: Interactions are officially noted for medicines that suppress the cough reflex (antitussives) or dry out bronchial secretions, which are sometimes found in OTC products. Furthermore, caution is advised when considering Fluditec alongside any medicine, like certain NSAIDs in cold/flu formulas, that is known to increase the risk of gastrointestinal bleeding.


Q: Does Fluditec interact with commonly consumed substances like alcohol?

A: Some liquid formulations of Fluditec contain ethanol (alcohol) as an excipient. Regulatory documents include a warning that the alcohol content in certain liquid formulations may be harmful to individuals with conditions such as alcoholism or liver disease. Therefore, caution is generally advised regarding the alcohol excipient.


Q: Are there different strengths of Fluditec available for adults versus children?

A: Fluditec is manufactured in different formulation formats. Adult dosing is often delivered via capsules (e.g., 375 mg), while the oral solution (syrup), typically 250 mg per 5 ml, is also available. Both adults and children use the oral solution, but the appropriate volume administered changes based on the individual’s age.


Q: How long after starting treatment with Fluditec can a person typically expect to notice an improvement in symptoms?

A: Official prescribing information indicates that for chronic conditions, the initial higher daily dose is reduced to a lower maintenance dose only after a 'satisfactory response is obtained.' This pattern suggests that the intended response may occur relatively early in the course of treatment, but a specific onset time is not defined in regulatory documents.


Q: Is Fluditec intended for short-term relief, or is it used for long-term management of chronic lung conditions?

A: Regulatory summaries confirm that Fluditec may be used in both contexts. For the treatment of acute (short-term) respiratory issues, treatment is often subject to a defined time limit, such as 8 to 10 days. However, for chronic conditions, official labeling often outlines an initial regimen followed by a long-term maintenance dose.


Q: Is Fluditec generally available over the counter, or is it typically a prescription-only medication?

A: Regulatory labeling and prescribing information in many regions classify Fluditec as a 'Prescription Only Medicine.' This means that the product requires authorization from a licensed healthcare provider before it can be dispensed.


Q: What is the key difference between a mucolytic like Fluditec and an expectorant like guaifenesin?

A: Fluditec is officially classified as a mucolytic agent. Its primary function, as described in pharmacological studies, is to chemically change the structure of thick mucus by breaking down certain bonds to reduce its stickiness. This mechanism of altering the mucus structure is what distinguishes its class from other types of medicines used to clear phlegm, such as expectorants.


Q: How does the body eliminate or process Fluditec after it has done its job?

A: According to official pharmacological data, Fluditec is rapidly absorbed from the digestive tract. The majority of the medicine is disposed of via the kidneys within 24 hours of administration, primarily as the unchanged product or as metabolites (breakdown products).


Q: Does Fluditec contain sugar, and is there a sugar-free alternative available for people with diabetes?

A: Some liquid formulations of Fluditec do contain sugar (sucrose) or related components like maltitol. However, regulatory documents confirm that sugar-free formulations are also available to address the needs of patients with specific dietary restrictions or metabolic disorders like diabetes.


Q: Are there any ingredients in Fluditec that may cause a delayed allergic reaction, such as preservatives?

A: Official product information explicitly lists specific excipients, such as sodium methyl parahydroxybenzoate and sodium propyl parahydroxybenzoate, which are commonly used as preservatives. These substances are noted in the labeling to potentially cause allergic reactions, which may, in some cases, be delayed.


Q: Does Fluditec contain sodium, and is this a concern for individuals on a controlled sodium diet?

A: Official labeling indicates that some formulations, particularly the liquid solutions, may contain a measurable amount of sodium. This sodium content is noted as potentially being a factor to consider for patients who are on a doctor-recommended low-salt diet. The capsule forms, however, are usually considered 'essentially sodium-free.'


Q: Does Fluditec have a known potential to cause drowsiness or affect a person's ability to drive?

A: Official regulatory prescribing information addresses this concern directly. The medicine is formally stated to have no or negligible influence on the ability of a person to drive or operate machinery.


Q: What is the general recommendation for what to do if a dose of Fluditec is missed?

A: According to the patient information leaflet, if a person misses a dose, they should not worry, wait until the next dose is due, and the recommendation provided in the patient information leaflet is that a patient should not take a double dose to compensate.


Q: Are there any warnings regarding Fluditec use for people with pre-existing kidney or liver conditions?

A: While there are no general contraindications for overall kidney or liver impairment, some liquid formulations of Fluditec contain a small amount of alcohol (ethanol). Regulatory warnings advise caution for use in individuals with liver disease due to this component.


Q: Is it safe to take Fluditec with common pain relievers like paracetamol or ibuprofen?

A: Official guidance notes that caution is required when Fluditec is co-administered with medicines, such as NSAIDs (like Ibuprofen), that are known to increase the risk of stomach bleeding or ulcers. However, the most common non-NSAID pain reliever, Paracetamol (Acetaminophen), is generally not listed in specific interaction warnings.


Q: What are the signs and symptoms of a serious allergic reaction to Fluditec that require medical attention?

A: The official safety sheets note that signs of a serious allergic reaction may include a severe skin rash, difficulty swallowing or breathing, and swelling of the lips, face, throat, or tongue. The documentation advises that symptoms of this nature warrant immediate medical assistance.


Q: Does Fluditec have any documented interactions with herbal or dietary supplements?

A: Specific interactions with individual herbal or dietary supplements are not typically detailed in regulatory product information. Official guidance includes a recommendation to discuss all concomitant medicines, including herbal remedies, with a healthcare professional, as their interactions are not always fully tested.


Q: What information is available regarding the potential for Fluditec to be habit-forming?

A: Regulatory and clinical safety reviews do not list any potential for dependency, misuse, or habit-forming behavior in the official safety profile for the active ingredient, Carbocisteine.


Q: Is Fluditec generally used as a stand-alone treatment or as part of a combination therapy for lung conditions?

A: Fluditec is officially indicated as an 'adjunctive therapy' for respiratory disorders. This means it is intended to be used in addition to—rather than in place of—main treatments for lung conditions.


Q: What is the evidence regarding Fluditec's use in individuals who have asthma alongside a productive cough?

A: Fluditec is indicated for conditions characterized by excessive viscous mucus. However, official clinical commentary notes that evidence regarding its role in directly treating the underlying condition of asthma is limited or lacking.


Q: Are there different flavors or formats of Fluditec oral solution available?

A: Official product information confirms that the oral solution is manufactured in different formulations. Depending on the specific product, it may be available in various colors and flavors, such as orange or strawberry.


Q: What information do regulatory agencies provide on the long-term safety profile of Fluditec's active ingredient?

A: Regulatory safety data encompasses adverse events reported across all treatment durations. Clinical reviews suggest the active ingredient is generally well-tolerated in long-term use, with a safety profile that is comparable to placebo in studies lasting a year or more.


Q: What are the components of Fluditec, other than the active ingredient, that patients should be aware of?

A: The official labeling documents all inactive ingredients, or excipients, in the product. These may include substances like lactose monohydrate, maltitol, preservatives, and coloring agents, all of which carry specific warnings in the labeling for patients with certain allergies or metabolic conditions.

How should Fluditec be stored and disposed of?

How to Store and Dispose of Fluditec (Carbocisteine)

The storage and disposal of Fluditec are governed by specific regulatory requirements to maintain product stability and ensure safe environmental handling.

Storage Requirements

  • Temperature: The medicine must not be stored above 25 C.
  • Container and Protection: It must be stored in the original container and kept in the outer carton to protect from light.
  • Child Safety: Keep this medicine out of the sight and reach of children.

Stability After Opening

  • Oral Solution (Bottle): The product must be used within one month after the bottle is first opened.
  • Sachet: The contents of a sachet must be used immediately after opening.

Disposal

  • The product must not be disposed of via wastewater or household waste.
  • Ask your pharmacist how to dispose of any medicine that is no longer required.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Fluditec found in:

A-Z Index: